Iovance Biotherapeutics, Inc. (IOVA)

$11.99

+0.42 (+3.63%)
Rating:
Recommendation:
Neutral
Symbol IOVA
Price $11.99
Beta 0.906
Volume Avg. 5.02M
Market Cap 1.884B
Shares () -
52 Week Range 6.18-27.96
1y Target Est -
DCF Unlevered IOVA DCF ->
DCF Levered IOVA LDCF ->
ROE -54.79% Strong Sell
ROA -51.11% Strong Sell
Operating Margin -
Debt / Equity 27.04% Neutral
P/E -
P/B 3.41 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IOVA news


Dr. Maria Fardis
Healthcare
Biotechnology
NASDAQ Global Market

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.